Day One Biopharmaceuticals

Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company developing and commercializing targeted therapies for people of all ages living with life-threatening diseases, with an initial focus on pediatric and rare cancers. Its lead product OJEMDA (tovorafenib) is an FDA-approved treatment for relapsed or refractory pediatric low-grade glioma, and its pipeline includes DAY301 and the antibody-drug conjugate Emi-Le. Headquartered in Brisbane, California, the company was acquired by and is now part of the Servier Group as of March 2026. Day One was surfaced as a portfolio company of Canaan Partners and added to the API Evangelist network; it maintains a corporate and investor-relations web presence but publishes no public developer API, SDK, or programmatic surface.

Day One Biopharmaceuticals is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Oncology, Pediatric Cancer, and Rare Disease.

Day One Biopharmaceuticals’ developer surface includes support and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub

14.6/100 minimal ▬ flat Agent 4/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalOncologyPediatric CancerRare DiseasePharmaceuticalsBiotechnologyLife SciencesServier Group

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 14.6/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.9 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 4/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 4 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/day-one-biopharmaceuticals: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 2

The organization behind the API

Website

Website

Investors

Investors

Source (apis.yml)

aid: day-one-biopharmaceuticals
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/day-one-biopharmaceuticals.png
name: Day One Biopharmaceuticals
description: Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company developing and commercializing targeted
  therapies for people of all ages living with life-threatening diseases, with an initial focus on pediatric and rare cancers.
  Its lead product OJEMDA (tovorafenib) is an FDA-approved treatment for relapsed or refractory pediatric low-grade glioma,
  and its pipeline includes DAY301 and the antibody-drug conjugate Emi-Le. Headquartered in Brisbane, California, the company
  was acquired by and is now part of the Servier Group as of March 2026. Day One was surfaced as a portfolio company of Canaan
  Partners and added to the API Evangelist network; it maintains a corporate and investor-relations web presence but publishes
  no public developer API, SDK, or programmatic surface.
url: https://raw.githubusercontent.com/api-evangelist/day-one-biopharmaceuticals/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biopharmaceutical
- Oncology
- Pediatric Cancer
- Rare Disease
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Servier Group
apis: []
common:
- type: DomainSecurity
  url: security/day-one-biopharmaceuticals-domain-security.yml
- type: WellKnown
  url: well-known/day-one-biopharmaceuticals-well-known.yml
- type: LLMsTxt
  url: llms/day-one-biopharmaceuticals-llms.txt
- type: Website
  url: https://www.dayonebio.com
- type: PrivacyPolicy
  url: https://www.dayonebio.com/privacy-notice
- type: TermsOfService
  url: https://www.dayonebio.com/terms-of-use
- type: Support
  name: Contact Us
  url: https://www.dayonebio.com/our-company/contact-us/
- type: Investors
  url: https://ir.dayonebio.com/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence